The Department of Medical Sciences, together with WHO, organized the first meeting of the world to provide knowledge and guidelines for the quality control of cervical cancer vaccines to government regulators and vaccine manufacturers in each country.


Department of Medical Sciences, in collaboration with the World Health Organization (WHO), organized a workshop on "WHO Workshop on the Implementation of Recommendations to Assure the Quality, Safety, and Efficacy of Recombinant Human Papillomavirus Virus-Like Particles Vaccines" to the personnel of the government regulator. Include vaccine manufacturers in each country. Can be applied to the knowledge and in accordance with the guidelines. Of the World Health Organization to control the quality of vaccines against cervical cancer or HPV vaccines.

                   Dr. Apichai Mongkol, Director-General of the Department of Medical Sciences, said that HPV is the most common virus of reproductive tract infections in both women and men and cause cervical cancer. Although most of the HPV infections do not cause symptoms or disease. If the infection in the pathogenic species. As a result, the disease vaccination to prevent cervical cancer is highly effective in preterm infants. At present, the World Health Organization has improved the way it controls the quality and safety of HPV vaccines. The technical specifications of the HPV vaccine have been revised to include control information from production, quality control, clinical research and evaluate the quality of vaccines that contain multiple HPV variants produced in several countries and in clinical trials. This workshop was organized to provide government regulators and manufacturers with an understanding of the World Health Organization it also exchanges lessons learned between the government regulators and the producers of each country. Promote the implementation of the corresponding instructions.

                Dr. Apichai Continue that. The Department of Medical Sciences, in collaboration with the World Health Organization The meeting was held. Clinical trials of vaccines that are already registered in many countries, such as bivalent HPV vaccine (Type 16 and 18) and quadrivalent HPV vaccine (type 6, 11, 16 and 18) There are 9-valent HPV types (type 6, 11, 16, 18, 31, 33, 45 52 and 58) and HPV vaccines currently being studied in India and China. Clinical Research To have a better understanding. In assessing the quality, effectiveness, and safety of the World Health Organization


                 The participants included personnel from government regulators and vaccine manufacturers from each country, representatives from the World Health Organization A total of 45 delegates from Bangladesh, Bhutan, India, Indonesia, Korea, Malaysia, China, Nepal, Sri Lanka, Vietnam and Thailand, with staff from the WHO Regional Office for South East Asia (WHO SEARO) WAPRO) and the Eastern Mediterranean Region (WHO EMRO).